Temasek co-leads $35m pre-Series B round in China's Lupeng Pharma

Guangzhou-based Lupeng Pharmaceuticals, a clinical-stage firm that focuses on drug discovery and developing novel therapies for cancer, has snapped up $35 million in the second tranche of its pre-Series B round.